Skip to main content

A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Improvement of Mid-Face Volume

Recruiting · Phase 3 · NCT06734351

Conditions: Mid Face Volume Deficit

At a glance

Research payments reported, 2025
$352,488
U.S. investigators named
5
Sites paid
7
Planned or actual enrollment
231

About the trial

Sponsor
AbbVie
Tested
NOA VOLUME (device), VOLUMA XC (device)
Dates
Started 2024-12-16; completion 2029-07
Results posted
Not yet

Facial fullness is often regarded as a characteristic feature of a youthful face. Chronic reduction of collagen, elastin, and glycosaminoglycans contribute to the facial volume loss that characterizes the aging face. Volume restoration by replacing or augmenting soft tissue is critical to successful facial rejuvenation. NOA VOLUME is a crosslinked Hyaluronic Acid (HA) injectable gel formulated with lidocaine that was developed to provide a safe, minimally invasive method of improving mid-face volume deficit. The purpose of this study is to assess safety and effectiveness of NOA VOLUME in adult participants seeking improvement of mid-face volume compared to JUVÉDERM VOLUMA XC (VOLUMA XC). …

From ClinicalTrials.gov, last updated 2026-06-18. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $352,488 in research payments for this study in 2025 (44 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • H&h Research LLC $121,128
  • Skin Research Institute LLC $90,185
  • Westlake Dermatology PA $66,309
  • Facial Plastic Surgicenter LTD $47,034
  • Advanced Research Associates $9,500
  • Facial Plastic Surgicenter $9,167
  • Westlake Dermatology and Cosmetic Surgery $9,167

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.